The Role of TAR DNA Binding Protein 43 (TDP-43) As a CandiDate Biomarker of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Feb 11

PMID 36766521

Authors

Caterina Maria Gambino

Anna Maria Ciaccio

Bruna Lo Sasso

Rosaria Vincenza Giglio

Matteo Vidali

Luisa Agnello

Marcello Ciaccio

Affiliations

Soon will be listed here.

Abstract

Background: TAR DNA-binding protein 43 (TDP-43) aggregation in neuronal cells is recognized as a hallmark of amyotrophic lateral sclerosis (ALS). Although the literature strongly supports the pathogenetic role of TDP-43 in ALS pathogenesis, the role of TDP-43 as a biomarker of ALS is controversial. We performed a systematic review and meta-analysis to assess the diagnostic performance of TDP-43 for ALS.

Methods: Relevant publications were identified by a systematic literature search on PubMed and Web of Science from their inception to 8 April 2022.

Results: Seven studies, including 472 individuals, of whom 254 had ALS according to the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, met the inclusion criteria for our meta-analysis. According to the random-effects model, CSF TDP-43 levels are higher in ALS patients compared with control groups.

Conclusions: CSF TDP-43 could represent a biomarker of ALS, but further studies are mandatory before drawing conclusions.

Citing Articles

Intraventricular Administration of Exosomes from Patients with Amyotrophic Lateral Sclerosis Provokes Motor Neuron Disease in Mice.

Stavrovskaya A, Voronkov D, Pavlova A, Olshanskiy A, Belugin B, Ivanova M Acta Naturae. 2025; 16(4):73-80.

PMID: 39877010 PMC: 11771849. DOI: 10.32607/actanaturae.27499.

A Review of Biomarkers of Amyotrophic Lateral Sclerosis: A Pathophysiologic Approach.

Alshehri R, Abuzinadah A, Alrawaili M, Alotaibi M, Alsufyani H, Alshanketi R Int J Mol Sci. 2024; 25(20).

PMID: 39456682 PMC: 11507293. DOI: 10.3390/ijms252010900.

Sleep Apnea and Amyotrophic Lateral Sclerosis: Cause, Correlation, Any Relation?.

Ozdinler P Brain Sci. 2024; 14(10).

PMID: 39451992 PMC: 11505663. DOI: 10.3390/brainsci14100978.

Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

Taneva S, Todinova S, Andreeva T Int J Mol Sci. 2023; 24(18).

PMID: 37762599 PMC: 10531602. DOI: 10.3390/ijms241814296.

Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.

De Marchi F, Franjkic T, Schito P, Russo T, Nimac J, Chami A Biomedicines. 2023; 11(6).

PMID: 37371694 PMC: 10295684. DOI: 10.3390/biomedicines11061599.

References

Ren Y, Li S, Chen S, Sun X, Yang F, Wang H . TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. Front Neurol. 2021; 12:663637. PMC: 8236522. DOI: 10.3389/fneur.2021.663637. View

Strong M, Abrahams S, Goldstein L, Woolley S, McLaughlin P, Snowden J . Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(3-4):153-174. PMC: 7409990. DOI: 10.1080/21678421.2016.1267768. View

Agnello L, Lo Sasso B, Vidali M, Scazzone C, Gambino C, Piccoli T . Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. J Clin Med. 2022; 11(11). PMC: 9181117. DOI: 10.3390/jcm11113139. View

Brooks B . El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases.... J Neurol Sci. 1994; 124 Suppl:96-107. DOI: 10.1016/0022-510x(94)90191-0. View

Brown R, Al-Chalabi A . Amyotrophic Lateral Sclerosis. N Engl J Med. 2017; 377(2):162-172. DOI: 10.1056/NEJMra1603471. View

Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel B . Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2019; 12:25. PMC: 6382748. DOI: 10.3389/fnmol.2019.00025. View

Chen-Plotkin A, Lee V, Trojanowski J . TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010; 6(4):211-20. PMC: 2892118. DOI: 10.1038/nrneurol.2010.18. View

de Boer E, Orie V, Williams T, Baker M, De Oliveira H, Polvikoski T . TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020; . PMC: 7803890. DOI: 10.1136/jnnp-2020-322983. View

Chen H, Mitchell J . Mechanisms of TDP-43 Proteinopathy Onset and Propagation. Int J Mol Sci. 2021; 22(11). PMC: 8199531. DOI: 10.3390/ijms22116004. View

10.

Verma A . Tale of two diseases: amyotrophic lateral sclerosis and frontotemporal dementia. Neurol India. 2014; 62(4):347-51. DOI: 10.4103/0028-3886.141174. View

11.

Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides V, Zaganas I . Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dement Geriatr Cogn Disord. 2017; 44(3-4):144-152. DOI: 10.1159/000478979. View

12.

Jiang L, Ngo S . Altered TDP-43 Structure and Function: Key Insights into Aberrant RNA, Mitochondrial, and Cellular and Systemic Metabolism in Amyotrophic Lateral Sclerosis. Metabolites. 2022; 12(8). PMC: 9415507. DOI: 10.3390/metabo12080709. View

13.

Sephton C, Good S, Atkin S, Dewey C, Mayer 3rd P, Herz J . TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem. 2009; 285(9):6826-34. PMC: 2825476. DOI: 10.1074/jbc.M109.061846. View

14.

Arthur K, Calvo A, Price T, Geiger J, Chio A, Traynor B . Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016; 7:12408. PMC: 4987527. DOI: 10.1038/ncomms12408. View

15.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

16.

Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S . The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2011; 83(1):102-8. DOI: 10.1136/jnnp-2011-300188. View

17.

Colletti T, Agnello L, Spataro R, Guccione L, Notaro A, Lo Sasso B . Prognostic Role of CSF β-amyloid 1-42/1-40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis. Brain Sci. 2021; 11(3). PMC: 7997395. DOI: 10.3390/brainsci11030302. View

18.

Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P . TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2009; 65(4):470-3. DOI: 10.1002/ana.21612. View

19.

Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S . Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2010; 12(2):140-3. DOI: 10.3109/17482968.2010.541263. View

20.

Chien H, Lee C, Huang J . The Different Faces of the TDP-43 Low-Complexity Domain: The Formation of Liquid Droplets and Amyloid Fibrils. Int J Mol Sci. 2021; 22(15). PMC: 8348237. DOI: 10.3390/ijms22158213. View